MLC Dx, a San Francisco-based maker of molecular diagnostics, has secured $5.9 million in a Series B financing, according to a report in VentureWire. Mohr Davidow Ventures participated in the round, VentureWire said. MLC Dx is led by CEO Thomas Willis, who previously ran another Mohr Davidow portfolio company, ParAllelle Bioscience, before it was sold to Santa Clara, CA-based Affymetrix in 2005.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
